Kitamura M
Glomerular Engineering Unit, Department of Medicne, University College London Medical School, United Kingdom.
Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7387-91. doi: 10.1073/pnas.93.14.7387.
Using genetically engineered glomerular mesangial cells, an in vivo gene transfer approach was developed that specifically targets the renal glomerulus. By combining this system with a tetracycline (Tc)-responsive promoter, the present study aimed to create a reversible on/off system for site-specific in vivo control of exogenous gene activity within the glomerulus. In the Tc regulatory system, a Tc-controlled transactivator (tTA) encoded by a regulator plasmid induces target gene transcription by binding to a tTA-responsive promoter located in a response plasmid. Tc inhibits this tTA-dependent transactivation via its affinity for tTA. In double-transfected cells, therefore, the activity of a transgene can be controlled by Tc. Cultured rat mesangial cells were cotransfected with a regulator plasmid and a response plasmid that introduces a beta-galactosidase gene. In vitro, stable double-transfectant MtTAG cells exhibited no beta-galactosidase activity in the presence of Tc. However, following withdrawal of Tc from culture media, expression of beta-galactosidase was induced within 24 h. When Tc was again added, the expression was rapidly resuppressed. Low concentrations of Tc were sufficient to maintain the silent state of tTA-dependent promoter. MtTAG cells were then transferred into the rat glomeruli via renal artery injection. In the isolated chimeric glomeruli, expression of beta-galactosidase was induced ex vivo in the absence of Tc, whereas it was repressed in its presence. When Tc-pretreated MtTAG cells were transferred into the glomeruli of untreated rats, beta-galactosidase expression was induced in vivo within 3 days. Oral administration of Tc dramatically suppressed this induction. These data demonstrate the feasibility of using mesangial cell vectors combined with the Tc regulatory system for site-specific in vivo control of exogenous gene expression in the glomerulus.
利用基因工程改造的肾小球系膜细胞,开发了一种特异性靶向肾肾小球的体内基因转移方法。通过将该系统与四环素(Tc)响应启动子相结合,本研究旨在创建一个可逆的开/关系统,用于在体内特异性控制肾小球内外源基因的活性。在Tc调控系统中,由调节质粒编码的Tc控制反式激活因子(tTA)通过与位于响应质粒中的tTA响应启动子结合来诱导靶基因转录。Tc通过其对tTA的亲和力抑制这种tTA依赖性反式激活。因此,在双重转染的细胞中,转基因的活性可以由Tc控制。将培养的大鼠系膜细胞与引入β-半乳糖苷酶基因的调节质粒和响应质粒共转染。在体外,稳定的双重转染MtTAG细胞在存在Tc的情况下不表现出β-半乳糖苷酶活性。然而,从培养基中去除Tc后,β-半乳糖苷酶的表达在24小时内被诱导。当再次添加Tc时,表达迅速被重新抑制。低浓度的Tc足以维持tTA依赖性启动子的沉默状态。然后通过肾动脉注射将MtTAG细胞转移到大鼠肾小球中。在分离的嵌合肾小球中,在没有Tc的情况下体外诱导β-半乳糖苷酶的表达,而在其存在时则被抑制。当将经Tc预处理的MtTAG细胞转移到未处理大鼠的肾小球中时,β-半乳糖苷酶表达在3天内在体内被诱导。口服Tc可显著抑制这种诱导。这些数据证明了使用系膜细胞载体与Tc调控系统相结合在体内特异性控制肾小球中外源基因表达的可行性。